ES2127189T3 - Peptido nuevo biologicamente activo procedente de una rana (rana-cpn). - Google Patents

Peptido nuevo biologicamente activo procedente de una rana (rana-cpn).

Info

Publication number
ES2127189T3
ES2127189T3 ES91115079T ES91115079T ES2127189T3 ES 2127189 T3 ES2127189 T3 ES 2127189T3 ES 91115079 T ES91115079 T ES 91115079T ES 91115079 T ES91115079 T ES 91115079T ES 2127189 T3 ES2127189 T3 ES 2127189T3
Authority
ES
Spain
Prior art keywords
frog
cpn
rana
biologically active
active peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91115079T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2127189T3 publication Critical patent/ES2127189T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)

Abstract

UN NUEVO PEPTIDO QUE PRESENTA UNA ACCION NATRIURETICA Y UNA ACTIVIDAD VASODEPRESORA, Y POR TANTO, SE PUEDE APLICAR COMO REACTIVO DE DIAGNOSTICO. EL NUEVO PEPTIDO SE PRODUCE MEDIANTE EL PROCEDIMIENTO DE IGENIERIA GENETICA ASI COMO MEDIANTE METODOS DE PURIFICACION DE LOS SESOS DE RANAS O MEDIANTE SINTESIS QUIMICAS.
ES91115079T 1990-09-07 1991-09-06 Peptido nuevo biologicamente activo procedente de una rana (rana-cpn). Expired - Lifetime ES2127189T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238294A JP2977159B2 (ja) 1990-09-07 1990-09-07 カエル由来新規生理活性ペプチド（カエルｃｎｐ）

Publications (1)

Publication Number Publication Date
ES2127189T3 true ES2127189T3 (es) 1999-04-16

Family

ID=17028056

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91115079T Expired - Lifetime ES2127189T3 (es) 1990-09-07 1991-09-06 Peptido nuevo biologicamente activo procedente de una rana (rana-cpn).

Country Status (8)

Country Link
US (1) US5336759A (es)
EP (1) EP0475290B1 (es)
JP (1) JP2977159B2 (es)
AT (1) ATE175211T1 (es)
DE (1) DE69130695T2 (es)
DK (1) DK0475290T3 (es)
ES (1) ES2127189T3 (es)
GR (1) GR3029632T3 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
JP2010539002A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ウロジラチンの治療剤としての使用
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JPH04120095A (ja) 1992-04-21
DE69130695D1 (de) 1999-02-11
US5336759A (en) 1994-08-09
EP0475290B1 (en) 1998-12-30
GR3029632T3 (en) 1999-06-30
ATE175211T1 (de) 1999-01-15
DE69130695T2 (de) 1999-06-10
DK0475290T3 (da) 1999-08-30
JP2977159B2 (ja) 1999-11-10
EP0475290A1 (en) 1992-03-18

Similar Documents

Publication Publication Date Title
ES2127189T3 (es) Peptido nuevo biologicamente activo procedente de una rana (rana-cpn).
ES2127190T3 (es) Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo).
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
DE69834741D1 (de) Cellulase aus actinomycetes und herstellungsverfahren dafür
DE69829308D1 (de) Cellulase aus actinomycetes und herstellungsverfahren dafür
DK0655014T3 (da) Katalystisk forbrænding af organiske forbindelser
ATE199937T1 (de) Gensequenzen kodierend für flavonoid- stoffwechselwegenzyme und deren verwendung
DK72992D0 (da) Enzym
DK0696937T3 (da) Fremgangsmåde til behandling af spontant forbrændelige katalysatorer
BR9306794A (pt) Uso de zeólito beta contendo titánio como catalisador zeólito beta contendo titánio e processo para a produção de ácido adípico
ITTO991172A0 (it) Procedimento di purificazione biologica di un'acqua contenente perclor ato di ammonio.
DE69406214D1 (de) Verfahren zur Reinigung von für den menschlichen Verbrauch bestimmtem Wasser
ATE242814T1 (de) Diisopropylfluorophosphatase sowie deren verwendung und herstellung
DE69116803D1 (de) Peroxidase-Gen von mikrobischem Ursprung
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
BR9812254A (pt) Gene polimórfico cag de repetição contida e seus usos
ATE92077T1 (de) Enzymhemmer und methode zu dessen herstellung.
EP0572030A3 (en) Process for the purification of 4,4'-diaminodiphenylmethane.
IT9047825A0 (it) Impianto prefabbricato per il procedimento di trattamento di depurazione di liquami fognari cittadini, o scarichi industriali.
FR2711639B3 (fr) Procédé perfectionné d'épuration d'eaux usées du type "à boues activées", permettant d'accroître les rendements d'épuration.
TH31976A (th) การทำโพรพิลีน ออกไซด์ให้บริสุทธิ์
ITTO930166A1 (it) Procedimento per il trattamento di flussi reflui della produzione di n-fosfonometilglicina.
IT8819389A0 (it) Procedimento per depurazione di acque di scarico industriale.
IT8941638A0 (it) Procedimento ed impianto per il recupero di bitartrato di potassio dalle acque reflue di rigenerazione di impianti di deionizzazione del mosto d'uva.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475290

Country of ref document: ES